MONT-SAINT-GUIBERT, Belgium, July 07, 2021– (COMMERCIAL THREAD) – Regulatory news:
Celyad Oncology SA (Brussels: CYAD) (Paris: CYAD) (NASDAQ: CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on discovery and cancer, today announced that the Scientific Director , Dr David Gilham, will participate in a panel discussion entitled “Cell Therapies in the Next Decade” to be held on Wednesday July 14eat 8:55 am EST at the William Blair Biotech Focus 2021 conference which will take place virtually July 14-15, 2021. The leadership team will also participate in one-on-one investor meetings throughout the conference.
A live audio webcast of the discussion is accessible via the Events section of the Company’s website.
About Celyad Oncology SA
Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric T (CAR T) antigen therapies for cancer. The Company is developing a pipeline of candidates for allogeneic (ready-to-use) and autologous (personalized) CAR T cell therapy for the treatment of hematologic malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.
This press release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncology pipelines and the financial condition, results of operations and business prospects. Forward-looking statements may involve known and unknown risks and uncertainties which could cause the actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include the expected launch date of the Phase 1 trial by the end of 2020, our development of additional allogeneic candidates based on shRNAs from our CYAD-200 series into a clinical trial, and the duration and severity of the COVID-19 pandemic. and the government measures implemented to respond to them. A further list and description of these risks, uncertainties and other risks can be found in the documents and reports of the Securities and Exchange Commission (SEC) of Celyad Oncology, including in its annual report on Form 20-F filed with the SEC March 25, 2020. and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and actual results of Celyad Oncology may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations in this regard or any change in the events, conditions or circumstances upon which such statement is based, except as required by law. law or regulation.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20210707005671/en/
Investor and media contacts:
Communication & Investor Relations Director
LifeSci Advisors, LLC